Endocrine Abstracts

Introduction: Following extensive research activity to develop an effective hormonal approach to control male fertility, little is known concerning attitudes of men and women towards male contraception in different countries. Although several pharmaceutical companies have conducted studies in male contraception, a full clinical development programme to obtain approval for one of the hormonal methods has never been initiated.Methods: Several studies and s...

Background: Testosterone substitution with favourable kinetics and tolerance is important for hypogonadal men. Intramuscular injections of long-acting testosterone undecanoate (TU) offer a convenient modality.Methods: We report data from 281 patients (134 with primary, 88 with secondary hypogonadism and 59 with late-onset (‘mixed’ or ‘metabolic’) hypogonadism aged 15 to 72 years (mean 40±13 years) receiving altogether 4913 intram...

Introduction: Hypogonadism is associated with metabolic syndrome and all its individual components. This study analysed effects of normalization of serum testosterone in mainly elderly, hypogonadal men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 66 months.<...

Introduction: Testosterone therapy for hypogonadal men has been used for decades. However, there are still concerns regarding the safety of this treatment, particularly in elderly men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 66 months.<p class="abst...

Introduction: Obesity is associated with reduced testosterone, and low testosterone induces weight gain. This study analysed the effects of normalization of serum testosterone in mainly elderly, hypogonadal men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤ 3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 6...

Objectives: Elderly men often show a concurrence of a decline of testosterone with features of the metabolic syndrome.Materials and methods: One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral testosterone undecanoate for 42 months as the sole intervention.Results: Plasma testosterone rose from 9.3±1.7 to 18.7±2.1 nmol/l reaching...

Objectives: To investigate the safety of the administration of long-acting parenteral testosterone undecanoate (TU) to hypogonadal, mainly elderly men.Design and methods: One hundred and twenty-two men of a mean age of 59.5±6.0 years, with baseline testosterone 5.9–12.1 nmol/l were treated with parenteral TU. These 122 patients were followed for 42 months.Results: Plasma levels of testosterone rose from 9.3±1.7 to 18...

Objective: A reliable form of androgen substitution therapy in terms of favorable kinetics and tolerance as well as effective restoration of androgenicity is paramount in hypogonadal men. A feasible modality is the intramuscular injection of the long-acting ester testosterone undecanoate (TU).Design: We report data from 22 patients (15 with primary and 7 with secondary hypogonadism) aged 30 to 65 years (mean 43.8±8 years) who received injections of ...

BACKGROUND: DHEA and DHEAS, can be converted into Androstenedione, T and DHT as well as oestrogens by peripheral tissues. In normal men the conversion rate of IV-infused radiolabelled DHEAS to T is only 0.7%. In hypogonadal men, this conversion rate may be increased. We hypothesise that a pharmacological dose of orally administered DHEA may be able to raise plasma T into the normal range in hypogonadal men. METHODS: Local Ethical Committee Approval was obtained. Two groups (n=...

Introduction: Men with the metabolic syndrome have low plasma testosterone (T) levels. We aimed to study whether normalization of plasma T in such men improved features of the metabolic syndrome over the longer term.Design/methods: 145 men, 35 to 70 years, with the metabolic syndrome and hypogonadism (baseline total testosterone level <12.0 nmol/l or calculated free T level <225 pmol/l). They had received treatment for 30 weeks with either parent...